Liberia

in page functions
[French]
Liberia
Total population (2017) 4,730,436
Birth cohort (2017) 160,474
Surviving Infants (surviving to 1 year per year, 2017) 151,948
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 53/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 70/1000
World Bank Index, IDA (2015) 3.10
Gross Nation Income (per capita US$, 2015) 380
Co-financing group (2018) Initial self-financing
No. of districts/territories (2016) 15

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Liberia

Type of support

Approvals

2001-2022 (US$)
(29 May 2018)

Commitments

2001-2022 (US$)
(29 May 2018)

Disbursements

2000-2018 (US$)
(29 May 2018)

% Disbursed

(29 May 2018)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $47,232,674 $57,975,878 $46,035,003
Cash Support (CASHSUPP) $198,500 $223,500 $198,500 100%
Cold Chain Equipment Optimisation Platform (CCEOP) $1,200,121 $1,200,121 $949,767 79%
Ebola EPI Recovery Plan (EEPIRP) $2,811,269 $2,811,269 $2,811,269 100%
Health system strengthening (HSS 1) $3,689,254 $3,689,254 $3,689,254 100%
Health system strengthening (HSS 2) $3,240,000 $3,240,000 $3,240,000 100%
Health system strengthening (HSS 3) $7,404,796 $11,840,000 $4,222,583 57%
HPV Demo (NVS) $234,348 $234,348 $235,757 101%
Immunisation services support (ISS) $2,188,750 $2,188,750 $2,188,750 100%
Injection Safety Devices (NVS) $157,000 $282,000 $193,512 123%
Injection safety support (INS) $360,500 $360,500 $266,500 74%
IPV (NVS) $272,639 $272,639 $240,510 88%
Measles-Follow-up campaign (NVS) $236,022 $236,022 $236,022 100%
Measles-Follow-up campaign op.costs (OPC) $501,000 $501,000 $501,000 100%
Penta (NVS) $11,038,813 $11,727,813 $11,776,471 107%
Pneumo (NVS) $8,675,210 $12,508,210 $10,406,600 120%
Product Switch Grant (PSG) $46,007 $46,007
Rotavirus (NVS) $2,111,389 $3,331,389 $1,869,947 89%
Vaccine Introduction Grant (VIG) $619,000 $619,000 $619,000 100%
Yellow Fever (NVS) $2,248,056 $2,664,056 $2,389,561 106%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Liberia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 92%
M:F sex ratio at birth (2017) 1.05
Household survey: DTP3 coverage for male (2012) 69.20%
Household survey: DTP3 coverage for female (2012) 73.80%
Household survey: Last DTP3 survey (2012) 71%
% districts achieving > 80% DTP3 coverage (2016) 80%
% districts achieving < 50% DTP3 coverage (2016) 0%
MCV WHO/UNICEF estimates (2016) 80%

Breakdown of support

Non-vaccine support Vaccine support
41% 59%
$18,686,623 $27,348,380

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Liberia

08 June 2018

Empire State Building

Red Nose Day 2018 raises record-breaking US$ 42 million

2018 was another record-breaking year of fun and fundraising for Red Nose Day USA. The money raised will support grantee partners to keep children and young people safe, healthy, educated and empowered.

19 May 2018

Ebola Q&A thumb

DR Congo Ebola outbreak response: Q&A with Gavi CEO Dr Seth Berkley

Gavi CEO Dr Seth Berkley answers questions about the planned deployment of Merck’s rVSV-ZEBOV vaccine to counter the ongoing Ebola outbreak in the north west of the Democratic Republic of the Congo (DRC).

07 May 2018

Rwanda - FB Live

New management training for immunisation leaders kicks-off in Kigali

24 managers from five Gavi-supported countries will attend the first round of the nine-month programme.

close icon

modal window here